ENVB Key Statistics, Chart & Performance
The current stock price of ENVB is 2.37 USD. In the past month the price decreased by -41.91%. In the past year, price decreased by -88.1%.
ENVB Technical Analysis
ENVB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ENVB. ENVB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ENVB Financial Highlights
Over the last trailing twelve months ENVB reported a non-GAAP Earnings per Share(EPS) of -255.6. The EPS increased by 79.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -257.81% | ||
| ROE | -325.39% | ||
| Debt/Equity | 0 |
ENVB Forecast & Estimates
7 analysts have analysed ENVB and the average price target is 122.4 USD. This implies a price increase of 5064.56% is expected in the next year compared to the current price of 2.37.
ENVB Ownership
ENVB Latest News, Press Relases and Analysis
ENVB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.53 | 965.082B | ||
| JNJ | JOHNSON & JOHNSON | 20.76 | 572.907B | ||
| MRK | MERCK & CO. INC. | 22.54 | 297.222B | ||
| PFE | PFIZER INC | 9.06 | 150.614B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.19 | 121.168B | ||
| ZTS | ZOETIS INC | 18.6 | 55.849B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.61 | 25.456B | ||
| VTRS | VIATRIS INC | 5.78 | 16.516B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.9 | 12.079B | ||
| AXSM | AXSOME THERAPEUTICS INC | 223.48 | 9.116B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ENVB
Company Profile
Enveric Biosciences Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Cambridge, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2009-07-21. Enveric Biosciences, Inc. is a biotechnology company. The firm is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The firm is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.
Company Info
ENVERIC BIOSCIENCES INC
245 First Street Riverview Ii 18Th Floor
Cambridge MASSACHUSETTS 34103 US
CEO: David Johnson
Employees: 5
Phone: 16174448400
ENVERIC BIOSCIENCES INC / ENVB FAQ
What does ENVB do?
Enveric Biosciences Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Cambridge, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2009-07-21. Enveric Biosciences, Inc. is a biotechnology company. The firm is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The firm is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.
Can you provide the latest stock price for ENVERIC BIOSCIENCES INC?
The current stock price of ENVB is 2.37 USD. The price decreased by -9.89% in the last trading session.
What is the dividend status of ENVERIC BIOSCIENCES INC?
ENVB does not pay a dividend.
What is the ChartMill technical and fundamental rating of ENVB stock?
ENVB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about ENVERIC BIOSCIENCES INC (ENVB) stock?
7 analysts have analysed ENVB and the average price target is 122.4 USD. This implies a price increase of 5064.56% is expected in the next year compared to the current price of 2.37.
What is the Price/Earnings (PE) ratio of ENVERIC BIOSCIENCES INC (ENVB)?
ENVERIC BIOSCIENCES INC (ENVB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-255.6).
What is the market capitalization of ENVB stock?
ENVERIC BIOSCIENCES INC (ENVB) has a market capitalization of 1.42M USD. This makes ENVB a Nano Cap stock.